HC Wainwright Has Lowered Expectations for CareDx (NASDAQ:CDNA) Stock Price

CareDx (NASDAQ:CDNA - Get Free Report) had its price target reduced by equities researchers at HC Wainwright from $26.00 to $25.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a "neutral" rating on the stock. HC Wainwright's price target indicates a potential upside of 32.28% from the company's current price. HC Wainwright also issued estimates for CareDx's Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.50) EPS.

CDNA has been the topic of a number of other reports. BTIG Research decreased their price target on CareDx from $40.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, November 5th. StockNews.com upgraded shares of CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday, February 26th. Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and lowered their price objective for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. Finally, Stephens restated an "overweight" rating and issued a $40.00 price objective on shares of CareDx in a research report on Thursday, February 27th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.83.

Remove Ads

CareDx Trading Down 7.4 %

NASDAQ:CDNA traded down $1.52 during mid-day trading on Monday, hitting $18.90. The company's stock had a trading volume of 714,685 shares, compared to its average volume of 842,000. The stock has a fifty day moving average of $22.65 and a 200-day moving average of $25.02. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -7.00 and a beta of 1.87. CareDx has a fifty-two week low of $7.42 and a fifty-two week high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, topping the consensus estimate of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million. On average, equities analysts anticipate that CareDx will post -0.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CareDx

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of CareDx by 7.1% during the fourth quarter. Vanguard Group Inc. now owns 4,859,732 shares of the company's stock worth $104,047,000 after purchasing an additional 323,554 shares in the last quarter. Bamco Inc. NY grew its position in shares of CareDx by 17.6% in the 4th quarter. Bamco Inc. NY now owns 2,207,299 shares of the company's stock valued at $47,258,000 after purchasing an additional 330,627 shares during the period. Fred Alger Management LLC grew its position in shares of CareDx by 7.3% in the 4th quarter. Fred Alger Management LLC now owns 1,613,992 shares of the company's stock valued at $34,556,000 after purchasing an additional 110,471 shares during the period. Invesco Ltd. raised its holdings in CareDx by 3.5% during the 4th quarter. Invesco Ltd. now owns 1,514,850 shares of the company's stock worth $32,433,000 after buying an additional 51,160 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in CareDx by 15.9% during the 4th quarter. Renaissance Technologies LLC now owns 1,432,198 shares of the company's stock worth $30,663,000 after buying an additional 196,298 shares during the period.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.